for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

73.10USD

Change

-0.20(-0.27%)

Volume

556,877

Today's Range

72.69

 - 

73.31

52 Week Range

65.26

 - 

87.79

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
73.30
Open
72.99
Volume
556,877
3M AVG Volume
205.30
Today's High
73.31
Today's Low
72.69
52 Week High
87.79
52 Week Low
65.26
Shares Out (MIL)
2,530.32
Market Cap (MIL)
184,333.50
Forward P/E
11.12
Dividend (Yield %)
3.57

Next Event

Merck & Co Inc at Barclays Global Healthcare Conference (Virtual)

Latest Developments

更多

Merck Says To Help Produce Johnson & Johnson's Covid-19 Vaccine

Merck Provides Update On Keytruda Indication In Metastatic Small Cell Lung Cancer In U.S.

Merck To Acquire Pandion Therapeutics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

1.92 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

52.4K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

6.507
Price To Earnings (TTM)
26.22
Price To Sales (TTM)
3.84
Price To Book (MRQ)
7.28
Price To Cash Flow (TTM)
17.21
Total Debt To Equity (MRQ)
125.57
LT Debt To Equity (MRQ)
100.17
Return on Investment (TTM)
11.22
Return on Equity (TTM)
8.05

Latest News

Latest News

UPDATE 7-Biden says will have enough COVID-19 vaccine for every U.S. adult by May

The United States will have enough COVID-19 vaccine for every American adult by the end of May, President Joe Biden said on Tuesday after Merck & Co agreed to make rival Johnson & Johnson's inoculation.

Merck to help make Johnson & Johnson's vaccine - Washington Post

Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine, the Washington Post reported on Tuesday, citing senior officials from U.S. President Joe Biden's administration.

UPDATE 1-Merck says FDA requires more data on its COVID-19 drug

Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.

Merck says FDA requires more data on its COVID-19 drug

Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.

UPDATE 2-Merck to buy drug developer Pandion Therapeutics for $1.85 bln

Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, expanding its portfolio of drugs that target autoimmune diseases.

Merck to buy drug developer Pandion Therapeutics for $1.85 bln

Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for $1.85 billion, to expand its portfolio of drugs that target autoimmune diseases. (Reporting by Manas Mishra in Bengaluru; Editing by Ramakrishnan M.)

CORRECTED-UPDATE 2-Merck in talks with governments, other drugmakers to produce COVID-19 shots (Feb. 10)

Merck & Co Inc said on Wednesday it was in talks with governments and companies to potentially help with manufacturing of COVID-19 vaccines that have been already authorized.

CORRECTED-Merck adds experimental COVID-19 therapy with OncoImmune deal (Nov. 23)

Merck & Co Inc has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients with severe or critical cases of COVID-19.

Merck in talks to possibly produce COVID-19 shots - WSJ

Merck & Co Inc is in talks with governments and companies to potentially help with manufacturing COVID-19 vaccines that have been already authorized, the Wall Street Journal reported on Wednesday.

UPDATE 8-One of the few top U.S. Black CEOs, Merck's Ken Frazier to retire

Merck & Co Inc said on Thursday Ken Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.

Merck warns against using anti-parasite drug to treat COVID-19

Drugmaker Merck & Co Inc on Thursday said its analysis of available data does not support the safety and efficacy of its anti-parasite drug, ivermectin, for the treatment of COVID-19.

Merck expects interim data on COVID-19 drug in first quarter

U.S. drugmaker Merck & Co Inc said on Thursday it was expecting early data from a trial of the experimental antiviral drug it was developing with Ridgeback Bio as early as the first quarter.

RPT-UPDATE 5-Merck CEO Kenneth Frazier to retire at the end of June

Merck & Co Inc said on Thursday Kenneth Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.

UPDATE 5-Merck CEO Kenneth Frazier to retire at the end of June

Merck & Co Inc said on Thursday Kenneth Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.

Merck CEO Kenneth Frazier to retire

Merck & Co said on Thursday Chief Executive Officer Kenneth Frazier will retire and will be replaced by Chief Financial Officer Robert Davis. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

TREASURIES-U.S. 10-year yield skids to three-week low on nagging virus woes

U.S. Treasury prices rose, pushing benchmark 10-year yields to a three-week low on Monday, as risk appetite ebbed after drugmaker Merck ended its COVID-19 vaccine program and amid persistent worries about surging virus cases and their potential for prolonged lockdowns. Yields...

US STOCKS SNAPSHOT-Nasdaq opens at record high ahead of big-tech earnings

The Nasdaq opened at a record high on Monday as markets geared up for a busy week of earnings from mega-cap technology firms, while the Dow and S&P 500 came under pressure from a decline in Merck's shares.

UPDATE 1-Merck ends COVID vaccine program, cites inferior immune responses

Drugmaker Merck & Co said on Monday it would stop development of its two COVID-19 vaccines and focus pandemic research on treatments, with initial data on an experimental oral antiviral expected by the end of March.

Merck ends COVID vaccine program, cites inferior immune responses

Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.

UPDATE 1-U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up